Empowering two pipelines with dual reporting and batching in China and the United States - Medicilon won the "2023 Best Partner Award" from Gluetacs Therapeutics

 On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”.  Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony.

Medicilon and Gluetacs: Going in both directions, achieving each other’s achievements

Dr. Xiaobao Yang, Chairman and CEO of Gluetacs, affirmed the efficient service capabilities of Medicilon’s one-stop biopharmaceutical preclinical R&D service platform at the award ceremony, “In the past two years, Gluetacs’ GT919 and GT929 have been clinically approved in China and the United States, which is inseparable from Medicilon’s strong support.  Even for difficult trials, the Medicilon team was able to deliver beyond expectations, which makes us feel reassured and confident in our future collaboration.”

Dr. Jinna Cai, Chief Commercial Officer of Medicilon, said, “Thanks to Gluetacs for its continued recognition and trust in Medicilon. I very much look forward to the smooth progress of the clinical trials of Gluetacs' GT919 and GT929, and also look forward to the progress of more research and development pipelines.  We will continue to empower every project with high quality and efficiency, and help partners such as Gluetacs discover and develop more good and new drugs.” Medicilon’s one-stop shop empowers biopharmaceutical preclinical research and development

As one of the earliest CRO companies in China to provide a complete set of new drug clinical research applications that comply with both Chinese GLP and US GLP standards, Medicilon now has a 29,000 square meter GLP laboratory and has established the Provantis GLP Tox data collection system in accordance with international standards, EMPOWER data collection management system, Chromeleon chromatography data system, and LIMS system strengthen the standardization and traceability of the research process, and use SEND format to process data to ensure that clinical research applications to meet FDA requirements.  As of the end of 2023, Medicilon has provided drug research and development services to more than 2,000 clients around the world based on its one-stop biopharmaceutical preclinical research and development service platform. Medicilon has participated in the research and development of 420 new drugs and generic drug projects that have been approved for clinical use.

This commendation not only affirms the results of the collaboration between the two parties in the past year, but also strengthens confidence in future collaboration.  Medicilon will continue to innovate and improve the capabilities of its one-stop biopharmaceutical preclinical R&D service platform, empower more clients to create more innovation and value, and jointly promote the development and progress of the biopharmaceutical industry.

About Gluetacs Therapeutics

Gluetacs Therapeutics is a biopharmaceutical company focusing on the development of oral protein-degrading small molecule drugs, which is the first biopharmaceutical company incubated by ShanghaiTech University.  It was established in February 2020 and officially in operation in March 2021. It was founded by a number of scientists who have been working in the field of protein degradation for many years.  The company has intellectual property rights for the development platforms of molecular glue degraders (GLUE) and dual-mechanism degraders (GLUETACS), which has applied for and authorized nearly 100 patents in this field from different countries, and also has unique and differentiated technical routes and development strategies.  Gluetacs Therapeutics has independently established an artificial intelligence virtual screening platform, an in vitro drug efficacy screening platform, a pharmacokinetics platform, a proteomics platform and a tumor animal drug efficacy model platform, which could achieve the construction of a complete full-process drug research and development system.  Since its official operation in March 2021, Gluetacs Therapeutics has successfully promoted two drug candidates into clinical trials, fully verifying and demonstrating the ability of the GLUETACS® platform to rapidly discover drug candidates and advance pipelines.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.